Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | TFPI | P10646 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479372 | 0.95 | KDM1A (0.58) | OPRM1OPRK1KEAP1KDM1ATFPI | |
| SCHEMBL14479366 | 0.92 | OPRM1 (0.61) | OPRM1OPRK1KEAP1TFPI | |
| SCHEMBL14479341 | 0.91 | KDM1A (0.59) | OPRM1OPRK1KEAP1KDM1ATFPI | |
| SCHEMBL14479365 | 0.90 | KDM1A (0.61) | OPRM1OPRK1KEAP1KDM1ATFPI | |
| SCHEMBL14479433 | 0.90 | OPRM1 (0.64) | OPRM1OPRK1KEAP1KDM1ATFPI | |
| SCHEMBL17166400 | 0.89 | KDM1A (0.59) | OPRM1OPRK1KEAP1KDM1ATFPI | |
| SCHEMBL14479402 | 0.89 | KDM1A (0.60) | OPRM1OPRK1KEAP1KDM1ATFPI | |
| SCHEMBL14479411 | 0.87 | KDM1A (0.60) | KEAP1KDM1ATFPI | |
| SCHEMBL14479334 | 0.87 | KISS1R (0.68) | — | |
| SCHEMBL14479415 | 0.87 | KDM1A (0.56) | OPRM1OPRK1KEAP1KDM1ATFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005944-A1 | CXCR4 Receptor Compounds | CXCL12, CXCR4, CCR5 | OPRM1 393/4885OPRK1 160/4885MAPK8 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.